Jiangsu Hengrui Medicine repurchases shares for employee stock plan

Jiangsu Hengrui Medicine, a company listed on the Hong Kong Stock Exchange, announced a repurchase of its A-shares on September 24, 2025. The company repurchased 140,000 A-shares, held as treasury shares, as part of an A-share employee stock ownership plan. This transaction took place on the Shanghai Stock Exchange, where the A-shares are listed.

The repurchase represents 0.002% of the company's existing issued shares, excluding treasury shares. The shares were acquired at prices ranging from RMB 69.3 to RMB 69.6 per share. The total expenditure for this repurchase amounted to RMB 9,725,200. Following this transaction, the number of issued shares (excluding treasury shares) stands at 6,368,051,964, while treasury shares increased to 10,950,310, bringing the total number of issued shares to 6,379,002,274.

The company confirmed that the share repurchase was conducted in accordance with local rules governing such activities on the Shanghai Stock Exchange. This disclosure aligns with reporting requirements under the Hong Kong Stock Exchange Listing Rules, specifically regarding changes in issued share capital and treasury shares.